JP6298051B2 - 薬物送達デバイスの装置 - Google Patents
薬物送達デバイスの装置 Download PDFInfo
- Publication number
- JP6298051B2 JP6298051B2 JP2015524732A JP2015524732A JP6298051B2 JP 6298051 B2 JP6298051 B2 JP 6298051B2 JP 2015524732 A JP2015524732 A JP 2015524732A JP 2015524732 A JP2015524732 A JP 2015524732A JP 6298051 B2 JP6298051 B2 JP 6298051B2
- Authority
- JP
- Japan
- Prior art keywords
- cap
- section
- seal
- cavity
- recess
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000012377 drug delivery Methods 0.000 title claims description 18
- 238000007373 indentation Methods 0.000 claims description 46
- 238000007789 sealing Methods 0.000 claims description 39
- 229940079593 drug Drugs 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 27
- 238000004891 communication Methods 0.000 claims description 17
- 230000003993 interaction Effects 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 2
- 239000002585 base Substances 0.000 description 13
- -1 human insulin Chemical compound 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229960002848 formoterol Drugs 0.000 description 3
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 3
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000012254 powdered material Substances 0.000 description 3
- 229960002052 salbutamol Drugs 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 2
- 229940112141 dry powder inhaler Drugs 0.000 description 2
- 108010015174 exendin 3 Proteins 0.000 description 2
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960001361 ipratropium bromide Drugs 0.000 description 2
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960001664 mometasone Drugs 0.000 description 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 2
- 229960002657 orciprenaline Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 1
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 description 1
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical class C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- PZSMUPGANZGPBF-UHFFFAOYSA-N 4-[5-(dithiolan-3-yl)pentanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCCCC1CCSS1 PZSMUPGANZGPBF-UHFFFAOYSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- PJFHZKIDENOSJB-UHFFFAOYSA-N Budesonide/formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=CC2(C)C2C1C1CC3OC(CCC)OC3(C(=O)CO)C1(C)CC2O PJFHZKIDENOSJB-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000027771 Obstructive airways disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- LDXDSHIEDAPSSA-OAHLLOKOSA-N Ramatroban Chemical compound N([C@@H]1CCC=2N(C3=CC=CC=C3C=2C1)CCC(=O)O)S(=O)(=O)C1=CC=C(F)C=C1 LDXDSHIEDAPSSA-OAHLLOKOSA-N 0.000 description 1
- 206010070774 Respiratory tract oedema Diseases 0.000 description 1
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 1
- ZBVKEHDGYSLCCC-UHFFFAOYSA-N Seratrodast Chemical compound O=C1C(C)=C(C)C(=O)C(C(CCCCCC(O)=O)C=2C=CC=CC=2)=C1C ZBVKEHDGYSLCCC-UHFFFAOYSA-N 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000003938 Thromboxane Receptors Human genes 0.000 description 1
- 108090000300 Thromboxane Receptors Proteins 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- YYAZJTUGSQOFHG-IAVNQIGZSA-N [(6s,8s,10s,11s,13s,14s,16r,17r)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate;2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]eth Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)C1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O YYAZJTUGSQOFHG-IAVNQIGZSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960003060 bambuterol Drugs 0.000 description 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229940080593 budesonide / formoterol Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960004399 carbocisteine Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 229960001386 carbuterol Drugs 0.000 description 1
- KEMXXQOFIRIICG-UHFFFAOYSA-N carbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(NC(N)=O)=C1 KEMXXQOFIRIICG-UHFFFAOYSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960001117 clenbuterol Drugs 0.000 description 1
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
- 229940109248 cromoglycate Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960001271 desloratadine Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229950000579 enprofylline Drugs 0.000 description 1
- QVDKSPUZWYTNQA-UHFFFAOYSA-N enprofylline Chemical compound O=C1NC(=O)N(CCC)C2=NC=N[C]21 QVDKSPUZWYTNQA-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 229940114006 fluticasone / salmeterol Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- OXLZNBCNGJWPRV-UHFFFAOYSA-N hexoprenaline Chemical compound C=1C=C(O)C(O)=CC=1C(O)CNCCCCCCNCC(O)C1=CC=C(O)C(O)=C1 OXLZNBCNGJWPRV-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 229960004078 indacaterol Drugs 0.000 description 1
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 229960001508 levocetirizine Drugs 0.000 description 1
- 229950008204 levosalbutamol Drugs 0.000 description 1
- 229940127212 long-acting beta 2 agonist Drugs 0.000 description 1
- 229940125389 long-acting beta agonist Drugs 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960001913 mecysteine Drugs 0.000 description 1
- MCYHPZGUONZRGO-VKHMYHEASA-N methyl L-cysteinate Chemical compound COC(=O)[C@@H](N)CS MCYHPZGUONZRGO-VKHMYHEASA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-N methyl sulfate Chemical compound COS(O)(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-N 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
- 229960004398 nedocromil Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 229960001609 oxitropium bromide Drugs 0.000 description 1
- LCELQERNWLBPSY-KHSTUMNDSA-M oxitropium bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 LCELQERNWLBPSY-KHSTUMNDSA-M 0.000 description 1
- RLANKEDHRWMNRO-UHFFFAOYSA-M oxtriphylline Chemical compound C[N+](C)(C)CCO.O=C1N(C)C(=O)N(C)C2=C1[N-]C=N2 RLANKEDHRWMNRO-UHFFFAOYSA-M 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
- 229960002288 procaterol Drugs 0.000 description 1
- FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 229950004496 ramatroban Drugs 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960002720 reproterol Drugs 0.000 description 1
- WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 229960003090 seratrodast Drugs 0.000 description 1
- 229940127211 short-acting beta 2 agonist Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960000859 tulobuterol Drugs 0.000 description 1
- 229940127210 ultra-LABA Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
- 229960004764 zafirlukast Drugs 0.000 description 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
- 229960005332 zileuton Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0091—Inhalators mechanically breath-triggered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
- A61M15/0025—Mouthpieces therefor with caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/062—Desiccants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Anesthesiology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Closures For Containers (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
ヒトインスリンのようなインスリン、例えば組換えヒトインスリン、もしくはヒトインスリン類似体もしくは誘導体、グリカゴン様ペプチド(GLP−1)もしくはその類似体もしくはその誘導体、もしくはエキセンジン−3もしくはエキセンジン−4、もしくはエキセンジン−3もしくはエキセンジン−4の類似体もしくは誘導体;
短時間作用型β2アゴニスト(例えばサルブタモール、アルブテロール、レボサルブタモール、フェノテロール、テルブタリン、ピルブテロール、プロカテロール、ビトルテロール、リミテロール、カルブテロール、ツロブテロール、レプロテロール)、長時間作用型β2アゴニスト(LABA、例えばアルホルモテロール、バンブテロール、クレンブテロール、ホルモテロール、サルメテロール)、ウルトラLABA(例えばインダカテロール)、もしくは別のアドレナリン作動薬(例えばエピネフリン、ヘキソプレナリン、イソプレナリン(イソプロテレノール)、オルシプレナリン(メタプロテレノール))のようなアドレナリン作動薬;
グルココルチコイド(例えばベクロメタゾン、ブデソニド、シクレソニド、フルチカゾン、モメタゾン、フルニソリド、ベタメタゾン、トリアムシノロン);
抗コリン作用薬もしくはムスカリンアンタゴニスト(例えば臭化イプラトロピウム、臭化オキシトロピウム、臭化チオトロピウム);
肥満細胞安定化薬(例えばクロモグリケート、ネドクロミル);
キサンチン誘導体(例えばドキソフィリン、エンプロフィリン、テオブロミン、テオフィリン、アミノフィリン、コリンテオフィリネート);
ロイコトリエンアンタゴニスト(例えばモンテルカスト、プランルカスト、ザフィルルカスト)のようなエイコサノイド阻害剤、リポキシゲナーゼ阻害剤(例えばジロイトン)、もしくはトロンボキサン受容体アンタゴニスト(例えばラマトロバン、セラトロダスト);
ホスホジエステラーゼタイプ4阻害剤(例えばロフルミラスト);
抗ヒスタミン薬(例えばロラタジン、デスロラタジン、セチリジン、レボセチリジン、フェキソフェナジン);
アレルゲン免疫療法(allergen immunotherapy)(例えばオマリズマブ);
粘液溶解薬(mucolytic)(例えばカルボシステイン、エルドステイン、メシステイン);
抗生物質もしくは抗真菌物質;
またはこれまでに言及した化合物種もしくは化合物のいずれか2つ、3つもしくはそれ以上の組合せ(例えばブデソニド/ホルモテロール、フルチカゾン/サルメテロール、臭化イプラトロピウム/サルブタモール、モメタゾン/ホルモテロール);
またはこれまでに挙げた化合物のいずれかの薬学的に許容される塩もしくは溶媒和物もしくはエステル。
2 本体
3 ベース部材
4 面
5 くぼみ
6 遠位端面
7 開端
8 閉端
9 キャビティ
10 セクション
11 シール
12 封止面
13 回転ストップ面
14 対応面
15 把持セクション
16 チャネル
17 通路
18 ねじ連結
19 回転部材
20 キャップ連結要素
21 本体連結要素
22 用量供給ピン
23 用量供給孔
24 リザーバ
25 薬物
26 ばね
27 壁部
28 デシケータ
29 マウスピース
30 第1の入口
31 第2の入口
32 流路
100 装置
200 薬物送達デバイス
d 軸方向距離
A 長手方向軸
Claims (15)
- 薬物送達デバイス(200)用の装置(100)であって、該装置(100)は:
キャビティ(9)を画成するキャップ(1)と、
本体(2)と
を含み、
ここで、キャップ(1)および本体(2)のうちの一方は、くぼみ(5)を含み、
キャップ(1)および本体(2)のうちの他方は、封止面(12)を含むシール(11)を含み、
キャップ(1)および本体(2)は、キャップ(1)が本体(2)に着脱可能に取り付け可能なように構成され、
キャップ(1)が取り付けられるとき、シール(11)の封止面(12)は、キャビティ(9)のセクション(10)を封止し、
A)キャップ(1)がくぼみ(5)を含む場合:
該くぼみ(5)は、キャビティ(9)のセクション(10)から離れているシール(11)の側に配置され、本体(2)からキャップ(1)が取り外されるとき、くぼみ(5)は、キャビティ(9)のセクション(10)に面しているシール(11)の側に向かって動かされ、くぼみ(5)の少なくとも一部が封止面(12)を通過すると、くぼみ(5)のこの部分はキャビティ(9)と環境との間に通路(17)を確立し、
B)本体(2)がくぼみ(5)を含む場合:
シール(11)は、キャビティ(9)のセクション(10)から離れているくぼみ(5)の側に配置され、本体(2)からキャップ(1)が取り外されるとき、シール(11)は、キャビティ(9)のセクション(10)に面しているくぼみ(5)の側に向かって動かされ、封止面(12)がくぼみ(5)の少なくとも一部を通過すると、くぼみ(5)のこの部分はキャビティ(9)と環境との間に通路(17)を確立する、
前記装置。 - キャップ(1)は、くぼみ(5)を含み、本体(2)は、シール(11)を含む、請求項1に記載の装置。
- くぼみ(5)は、キャップ(1)の開端(7)までの距離が、キャップ(1)の閉端(
8)までの距離よりも短くなるように配置される、請求項1または2に記載の装置。 - 本体(2)は、キャップ(1)が取り外されるときに環境と本体(2)の内部との間に連通を確立するように配置される少なくとも1つの開口部(29、30、31)を含み、本体(2)のこの開口部は、キャップ(1)が取り付けられるとき、キャビティ(9)のセクション(10)内に配置される、請求項1〜3のいずれか1項に記載の装置。
- 開口部(29、30、31)は、セクション(10)の外側に配置される本体(2)の内部領域との連通を確立するように構成され、セクション(10)および内部領域は、キャップが取り付けられているときは封止部分を画成する、請求項4に記載の装置。
- 本体(2)からのキャップ(1)の取り外しは、セクション(10)内に発生する減圧に打ち勝つために力が及ぼされる必要がある、キャップ(1)と本体(2)の相対的な軸方向運動を含み、くぼみ(5)は、キャップ(1)が取り付けられるときの封止面(12)とくぼみ(5)との間の軸方向距離(d)によってある程度決定される前記力を減少させるように配置される、請求項1〜5のいずれか1項に記載の装置。
- くぼみ(5)は、該くぼみ(5)を含むキャップ(1)および本体(2)のうちの一方の主軸の範囲に対して異なるように傾斜する少なくとも2つの側面によって境界が定められる、請求項1〜6のいずれか1項に記載の装置。
- 本体(2)へのキャップ(1)の取り付けは、本体(2)に対するキャップ(1)の閉回転方向の回転閉鎖運動を含み、主軸の範囲に対してより小さい角度を画成する側面は、回転ストップ面(13)を形成し、該回転ストップ面(13)は、キャップ(1)が本体(2)に取り付けられるとき、回転ストップ面(13)とキャップ(1)および本体(2)のうちの他方にある対応面(14)との相互作用によって、本体(2)に対するキャップ(1)のさらなる閉鎖回転を阻止するように構成される、請求項7に記載の装置。
- 本体(2)からのキャップ(1)の取り外しは、本体(2)に対するキャップ(1)の開回転方向の回転開放運動を含み、キャップ(1)が取り付けられるとき、くぼみ(5)は、キャップ(1)が本体に対して開回転方向に回転されるときに360°未満の回転角度内において通路(17)が確立されるように配置される、請求項1〜8のいずれか1項に記載の装置。
- キャップ(1)および本体(2)の一方は、円周方向に配置される複数のくぼみ(5)を含む、請求項1〜9のいずれか1項に記載の装置。
- くぼみ(5)は、異なる近接するくぼみの近接する側面が、くぼみを含むキャップ(1)および本体(2)のうちの一方の主軸の範囲に対して異なるように傾斜するように配置される、請求項10に記載の装置。
- 本体(2)は、互いに回転可能に連結されるベース部材(3)と回転部材(19)とを含み、シール(11)が本体(2)上に提供されるとき、シール(11)はベース部材(3)上に提供され、キャップ(1)が取り付けられるとき、回転部材(19)はセクション(10)内に配置される、請求項1〜11のいずれか1項に記載の装置。
- 本体(2)は、キャップが取り付けられるとき、キャビティ(9)のセクション(10)内に配置される、マウスピース(29)を含む、請求項1〜12のいずれか1項に記載の装置。
- 請求項1〜13のいずれか1項に記載の装置を含む薬物送達デバイス(200)であって、本体(2)は、可動壁部(27)を含む薬物リザーバ(24)を含み、該デバイス(200)は、吸入器である、前記薬物送達デバイス。
- 装置は、本体(2)からのキャップ(1)の取り外しの間、用量供給孔(23)がリザーバ(24)から引き出され、それによって薬物(25)の用量がリザーバ(24)から引き出され、リザーバ(24)の壁部(27)が封止されたセクション(10)内に発生する減圧を受けるように構成される、請求項14に記載の薬物送達デバイス(200)。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12178704.8 | 2012-07-31 | ||
| EP12178704 | 2012-07-31 | ||
| PCT/EP2013/065747 WO2014019940A1 (en) | 2012-07-31 | 2013-07-25 | Arrangement for a drug delivery device |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015523179A JP2015523179A (ja) | 2015-08-13 |
| JP2015523179A5 JP2015523179A5 (ja) | 2016-08-04 |
| JP6298051B2 true JP6298051B2 (ja) | 2018-03-20 |
Family
ID=46980726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015524732A Expired - Fee Related JP6298051B2 (ja) | 2012-07-31 | 2013-07-25 | 薬物送達デバイスの装置 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150165138A1 (ja) |
| EP (1) | EP2879743B1 (ja) |
| JP (1) | JP6298051B2 (ja) |
| KR (1) | KR20150030256A (ja) |
| CN (1) | CN104519934B (ja) |
| AU (1) | AU2013298673B2 (ja) |
| BR (1) | BR112015002067A2 (ja) |
| CA (1) | CA2880242A1 (ja) |
| DK (1) | DK2879743T3 (ja) |
| IL (1) | IL236354A0 (ja) |
| IN (1) | IN2014KN03007A (ja) |
| MX (1) | MX2015001321A (ja) |
| RU (1) | RU2637627C2 (ja) |
| TW (1) | TWI602590B (ja) |
| WO (1) | WO2014019940A1 (ja) |
| ZA (1) | ZA201409293B (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110475909B (zh) | 2017-03-30 | 2021-12-24 | 古河电气工业株式会社 | 表面处理铜箔及使用其的覆铜层压板 |
| US11717621B2 (en) | 2019-06-24 | 2023-08-08 | De Motu Cordis Pty Ltd | Automatic dispenser for respiratory delivery device |
| US11793951B2 (en) | 2019-06-24 | 2023-10-24 | De Motu Cordis Pty Ltd | Automatic dispenser for respiratory delivery device and method |
| US10828432B1 (en) * | 2019-06-24 | 2020-11-10 | De Motu Cordis Pty Ltd | Respiratory delivery device and method |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3046983A (en) * | 1959-10-01 | 1962-07-31 | Grubb Thomas Christman | Variable dose inhaler |
| US3252446A (en) * | 1964-08-13 | 1966-05-24 | Carter S Ink Co | Friction closure |
| US3809299A (en) * | 1973-01-09 | 1974-05-07 | N Sand | Captive dispenser cap |
| US3982651A (en) * | 1974-11-18 | 1976-09-28 | W. Braun Company | Container and closure cap therefor |
| US4095596A (en) * | 1976-11-26 | 1978-06-20 | Smithkline Corporation | Nasal inhaler |
| GB8518280D0 (en) * | 1985-07-19 | 1985-08-29 | Johnsen Jorgensen Plastics Ltd | Container & closure assembly |
| DE69712324T2 (de) * | 1996-02-21 | 2002-08-29 | Schering Corp., Kenilworth | Inhalator für pulverartiges medikament |
| IT1308581B1 (it) * | 1999-12-03 | 2002-01-08 | Medel Italiana Srl | Apparato per nebulizzare un liquido, in particolare per uso medico. |
| DE10047722A1 (de) * | 2000-09-27 | 2002-04-11 | Schuckmann Alfred Von | Von Saugluftstrom des Benutzers aktivierbare Dosiervorrichtung |
| EP2497514B8 (de) * | 2002-09-16 | 2015-12-16 | Sanofi SA | Inhalator für pulverförmige, insbesondere medizinische Substanzen |
| TWI286944B (en) * | 2003-04-09 | 2007-09-21 | Bioactis | A device for applying medicine powder to nose |
| US20050284474A1 (en) * | 2004-06-25 | 2005-12-29 | Tseng Daniel C | Nebulising medicine cup fixture assembly |
| FR2911329B1 (fr) * | 2007-01-12 | 2009-04-17 | Rexam Pharma Soc Par Actions S | Ensemble de conditionnement et de distribution d'un liquide medical |
| DE102007056263A1 (de) * | 2007-11-22 | 2009-05-28 | Siegfried Generics International Ag | Dosiervorrichtung zur Inhalierung einer pulverförmigen Substanz |
| US9050433B2 (en) * | 2007-11-29 | 2015-06-09 | Glaxo Group Limited | Dispensing device |
| CN101945682B (zh) * | 2008-02-12 | 2013-12-04 | 阿斯利康(瑞典)有限公司 | 包含具有至少一个含药物的密封空腔的基座的吸入器 |
| EP2470436A4 (en) * | 2009-08-25 | 2013-03-27 | Scholle Corp | CLOSURE WITH ANGLED CAM SURFACES ON INNER AND OUTER PARTS |
-
2013
- 2013-07-25 MX MX2015001321A patent/MX2015001321A/es unknown
- 2013-07-25 US US14/418,577 patent/US20150165138A1/en not_active Abandoned
- 2013-07-25 CN CN201380038826.0A patent/CN104519934B/zh not_active Expired - Fee Related
- 2013-07-25 AU AU2013298673A patent/AU2013298673B2/en not_active Ceased
- 2013-07-25 CA CA2880242A patent/CA2880242A1/en not_active Abandoned
- 2013-07-25 KR KR20157002332A patent/KR20150030256A/ko not_active Withdrawn
- 2013-07-25 BR BR112015002067A patent/BR112015002067A2/pt not_active Application Discontinuation
- 2013-07-25 RU RU2015106978A patent/RU2637627C2/ru not_active IP Right Cessation
- 2013-07-25 DK DK13740036.2T patent/DK2879743T3/en active
- 2013-07-25 WO PCT/EP2013/065747 patent/WO2014019940A1/en not_active Ceased
- 2013-07-25 EP EP13740036.2A patent/EP2879743B1/en not_active Not-in-force
- 2013-07-25 JP JP2015524732A patent/JP6298051B2/ja not_active Expired - Fee Related
- 2013-07-30 TW TW102127207A patent/TWI602590B/zh not_active IP Right Cessation
-
2014
- 2014-12-17 ZA ZA2014/09293A patent/ZA201409293B/en unknown
- 2014-12-18 IL IL236354A patent/IL236354A0/en unknown
- 2014-12-22 IN IN3007KON2014 patent/IN2014KN03007A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2015106978A (ru) | 2016-09-20 |
| CN104519934A (zh) | 2015-04-15 |
| AU2013298673A1 (en) | 2015-02-19 |
| HK1206656A1 (en) | 2016-01-15 |
| ZA201409293B (en) | 2015-12-23 |
| IL236354A0 (en) | 2015-02-26 |
| EP2879743A1 (en) | 2015-06-10 |
| CN104519934B (zh) | 2017-07-07 |
| BR112015002067A2 (pt) | 2017-07-04 |
| MX2015001321A (es) | 2015-04-08 |
| US20150165138A1 (en) | 2015-06-18 |
| AU2013298673B2 (en) | 2016-09-22 |
| IN2014KN03007A (ja) | 2015-05-08 |
| TW201420141A (zh) | 2014-06-01 |
| WO2014019940A1 (en) | 2014-02-06 |
| JP2015523179A (ja) | 2015-08-13 |
| RU2637627C2 (ru) | 2017-12-05 |
| EP2879743B1 (en) | 2016-12-07 |
| KR20150030256A (ko) | 2015-03-19 |
| DK2879743T3 (en) | 2017-02-27 |
| CA2880242A1 (en) | 2014-02-06 |
| TWI602590B (zh) | 2017-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5970082B2 (ja) | 吸入デバイス | |
| JP5969051B2 (ja) | 吸入デバイス用の用量カウント機構(Dose Counting Mechanism)および吸入デバイス | |
| JP6298051B2 (ja) | 薬物送達デバイスの装置 | |
| JP2017511191A (ja) | 医用デバイスのための封止部材 | |
| JP6235483B2 (ja) | 薬物送達デバイスのための装置(arrangement)および装置を組み立てる方法 | |
| RU2647161C2 (ru) | Узел для ингаляционного устройства и использование уплотнительного элемента | |
| JP2018149356A (ja) | 吸入デバイス用アセンブリおよび封止部材の使用 | |
| JP2017516553A (ja) | 薬物送達デバイス用のカウンタ機構のためのアセンブリおよび薬物送達デバイス | |
| RU2615276C2 (ru) | Узел для ингаляционного устройства, использование организующего элемента и ингаляционного устройства | |
| HK1206656B (en) | Arrangement for a drug delivery device | |
| EP2874884A2 (en) | Metering element for an inhalation device and inhalation device comprising a metering element | |
| US20160051777A1 (en) | Metering element for an inhalation device and assembly for an inhalation device containing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160616 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160616 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170704 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171004 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180130 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180222 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6298051 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |